Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VIP236 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation of VIP236 (Q3W) | EXPERIMENTAL | Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer. Dosing occurs on D1 of each 21-day cycle |
| Dose Escalation of VIP236 (Q2W) | EXPERIMENTAL | Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer. Dosing occurs on D1 and D15 of each 28-day cycle. |
| Name | Type | Description |
|---|---|---|
| VIP236 (Q3W) | DRUG | VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle. |
| VIP236 (Q2W) | DRUG | VIP236 will be administered by IV infusion once every 2 weeks, for a 28-day cycle. |
Inclusion Criteria: * Adult patients aged \>/=18 years, able to provide informed consent and willing to comply with all study procedures. * Histologically confirmed advanced or metastatic solid tumors that are relapsed or refractory to standard of care. Subjects must have exhausted all available st...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
VIP236 is an investigational small molecule being developed for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is currently being studied in patients with advanced cancer as part of a Phase 1 clinical trial.
VIP236 is a small molecule, but its specific molecular target has not been disclosed. The drug is being investigated for its potential to treat neoplasms, and its mechanism of action is not publicly detailed in the available information.
VIP236 is being developed by Vincerx Pharma, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol VINC on the NASDAQ stock exchange.
VIP236 is in Phase 1 clinical development. A Phase 1 dose escalation study has been completed, which involved 29 patients with advanced cancer. The drug is still investigational and has not been approved by regulatory authorities.
VIP236 has been studied in a Phase 1 dose escalation trial with the identifier NCT05712889. This trial, titled 'Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer,' was conducted in the United States and Australia and has been completed.
VIP236 is not known to have any alternative names. It is a distinct investigational compound being developed by Vincerx Pharma, Inc. for the treatment of neoplasms.